Genome-based pharmacogenetics and the pharmaceutical industry.

doi:10.1038/nrd840

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Genome-based pharmacogenetics and the pharmaceutical industry.

Nature reviews. Drug discovery - 1 Jul 2002

Roses Allen D

Abstract excerpt

Pharmacogenetic capabilities have changed markedly since The SNP Consortium made a dense single-nucleotide polymorphism (SNP) map freely available in 2001. For more than 40 years, pharmacokinetics and pharmacodynamics of drug-metabolizing molecules were the focus of practical applications. Today, it is possible to use SNP-mapping technologies to create a genetic profile of each individual that can be used to...

Topics

Clinical Trials as Topic
Dideoxynucleosides
Drug Industry
Genetic Predisposition to Disease
Genome
Humans
Pharmacogenetics
Polymorphism, Single Nucleotide
Proteome

Source

Open in PubMed

Identifiers

PMID: 12120260
DOI: 10.1038/nrd840

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics